Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/68591
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | EPITHET: Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration |
Author: | Nagakane, Y. Christensen, S. Brekenfeld, C. Ma, H. Churilov, L. Parsons, M. Levi, C. Butcher, K. Peeters, A. Barber, P. Bladin, C. De Silva, D. Fink, J. Kimber, T. Schultz, D. Muir, K. Tress, B. Desmond, P. Davis, S. Donnan, G. |
Citation: | Stroke, 2011; 42(1):59-64 |
Publisher: | Lippincott Williams & Wilkins |
Issue Date: | 2011 |
ISSN: | 0039-2499 1524-4628 |
Statement of Responsibility: | Yoshinari Nagakane... Thomas E. Kimber... et al. for the EPITHET Investigators |
Abstract: | Background and Purpose—: The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregistration, which underestimates mismatch volumes. We hypothesized that assessing the extent of mismatch by coregistration of perfusion and diffusion MRI maps may more accurately allow the effects of alteplase vs placebo to be evaluated. Methods—: Patients were classified as having mismatch if perfusion-weighted imaging divided by coregistered diffusion-weighted imaging volume ratio was >1.2 and total coregistered mismatch volume was >=10 mL. The primary outcome was a comparison of infarct growth in alteplase vs placebo patients with coregistered mismatch. Results—: Of 99 patients with baseline diffusion-weighted imaging and perfusion-weighted imaging, coregistration of both images was possible in 95 patients. Coregistered mismatch was present in 93% (88/95) compared to 85% (81/95) with standard volumetric mismatch. In the coregistered mismatch patients, of whom 45 received alteplase and 43 received placebo, the primary outcome measure of geometric mean infarct growth was significantly attenuated by a ratio of 0.58 with alteplase compared to placebo (1.02 vs 1.77; 95% CI, 0.33–0.99; P=0.0459). Conclusions—: When using coregistration techniques to determine the presence of mismatch at study entry, alteplase significantly attenuated infarct growth. This highlights the necessity for a randomized, placebo-controlled, phase III clinical trial of alteplase using penumbral selection beyond 3 hours. |
Keywords: | magnetic resonance imaging mismatch penumbra tissue plasminogen activator |
Rights: | © 2011 American Heart Association, Inc. |
DOI: | 10.1161/STROKEAHA.110.580464 |
Published version: | http://dx.doi.org/10.1161/strokeaha.110.580464 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.